Semaglutide and body anxiety explained

People starting semaglutide for weight loss often report something unexpected: the body anxiety they expected to leave behind does not always lift. Instead it shifts shape. Concerns about excess weight give way to new worries about losing too much muscle, going too low on key micronutrients, or whether a quiet stomach is a warning sign or simply a drug effect. These concerns are not imaginary, and they are not fully resolved by the available research^[1].

What the research says about mood and anxiety on semaglutide

The picture is mixed and actively contested. A 2026 multicentre cohort study drawing on records from 13 South Korean hospitals found that semaglutide initiators carried a higher adjusted risk of anxiety disorder (hazard ratio 2.39, 95% CI 1.22-4.71) and depressive disorder (HR 3.42, 95% CI 1.51-7.74) compared with propensity score-matched non-initiators^[1]. The authors acknowledged that people who seek out a weight-loss medicine may already carry elevated baseline rates of these conditions, which limits what the hazard ratios can tell us about causation.

A separate national cohort study published in the Lancet Psychiatry, using Swedish health registers and a within-individual design comparing use versus non-use in the same 95,490 people with existing depression or anxiety, reached almost the opposite conclusion: semaglutide was associated with a 42% lower risk of mental illness worsening overall (aHR 0.58, 95% CI 0.51-0.65), including a 44% lower risk of worsening anxiety (aHR 0.62) and a 44% lower risk of worsening depression (aHR 0.56)^[2]. The within-individual approach reduces confounding from pre-existing conditions because each person serves as their own control.

Neither study is the final word. The Korean data come from a clinical cohort of new users; the Swedish data cover people already diagnosed with depression or anxiety. Both have limitations. What they agree on is that semaglutide's relationship with mood is not simple and warrants monitoring.

The muscle loss question

The concern about losing muscle alongside fat is grounded in biology. Weight loss from any intervention, including caloric restriction, tends to reduce both fat mass and lean mass. GLP-1 receptor agonists are no different. Preclinical work published in 2025 found that up to 45% of semaglutide-driven weight loss in mouse models could be attributed to skeletal muscle loss, and that this reduced muscle strength and suppressed mitochondrial gene expression^[3]. The study used co-administered ketone esters to blunt the effect, a finding that remains preclinical only.

Human trial data are less alarming but point in the same direction. The LEAN-PREP randomised trial protocol, registered in 2025, is directly testing whether resistance training and adequate protein intake can preserve lean mass during semaglutide and tirzepatide therapy. Results are pending. Until there is more human evidence, the question of how much muscle an individual is losing is genuinely unanswered for most patients.

Micronutrient concerns and appetite suppression

Semaglutide is a potent appetite suppressant. The drug's gastrointestinal effects, including nausea, reduced gastric emptying, and early satiety, are the mechanism behind much of the weight loss. They are also the mechanism behind the worry. Eating substantially less, particularly when nausea shapes food choices toward bland, easily tolerated options, creates real potential for inadequate intake of protein, iron, vitamin B12, and other micronutrients. This risk is not unique to semaglutide; it is recognised across calorie-restricted diets generally. The Ozempic prescribing information authorised by the EMA lists nausea (very common, >1 in 10 users) and decreased appetite as expected effects^[4].

Monitoring for nutritional deficiencies during significant weight loss is standard clinical practice, not a niche concern. If your doctor has not raised it, it is worth asking: a basic panel covering iron, B12, folate, and 25-OH vitamin D is a reasonable starting point for anyone on a programme causing consistent appetite reduction.

What this is not

The anxiety many semaglutide users describe about body composition, nutrition, and long-term health is not the same as a psychiatric adverse event. It is a cognitive response to a significant change that remains medically uncertain in some dimensions. The research on psychiatric risk is preliminary, contested, and not yet grounds for avoiding the drug if a clinician has recommended it. For people with a history of eating disorders, or those whose pre-existing anxiety attaches to body image, the shift in worry pattern described in community accounts is worth discussing with a clinician before and during treatment. See the semaglutide peptide page for the full regulatory and safety profile.

What we do not yet know

Long-term trials have not pre-specified mental health as a primary outcome. The LEAN-PREP trial will shed light on muscle preservation strategies but not on psychiatric outcomes. The evidence on anxiety, body image, and health vigilance is almost entirely observational or from community reports. What the field needs, and does not yet have, are randomised data on psychological outcomes in people without pre-existing psychiatric conditions who use semaglutide for weight loss over two or more years.